Pharmacological and Genetic Perturbation Establish SIRT5 as a Promising Target in Breast Cancer
暂无分享,去创建一个
J. Auwerx | R. Weiss | R. Cerione | Qingjie Zhao | Hening Lin | T. Southard | Fangyu Wang | Ying-Ling Chiang | J. Hong | Jing Hu | Bin He | Min Yang | Sushabhan Sadhukhan | J. Bai | Dennis A. Kutateladze | Bo Li | Yashira L. Negrón Abril | Irma R Fernandez | Brenna Remick | James Mullmann | Viviana Maymi | Ravi Dhawan | Dennis A Kutateladze
[1] J. Erickson,et al. SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis , 2019, Proceedings of the National Academy of Sciences.
[2] N. Curtin,et al. Warburg and Krebs and related effects in cancer , 2019, Expert Reviews in Molecular Medicine.
[3] M. Gnant,et al. Breast cancer , 2019, Nature Reviews Disease Primers.
[4] Hening Lin,et al. Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model. , 2019, Journal of medicinal chemistry.
[5] Hening Lin,et al. A Small‐Molecule SIRT2 Inhibitor That Promotes K‐Ras4a Lysine Fatty‐Acylation , 2019, ChemMedChem.
[6] Weiping Zheng,et al. Cyclic tripeptide-based potent and selective human SIRT5 inhibitors. , 2019, Medicinal chemistry (Shariqah (United Arab Emirates)).
[7] Ji Cao,et al. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity‐Dependent Inhibition, and On‐Target Anticancer Activities , 2018, ChemMedChem.
[8] Ce Li,et al. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer. , 2018, Oncology reports.
[9] W. Sippl,et al. Potent and Selective Inhibitors of Human Sirtuin 5. , 2018, Journal of medicinal chemistry.
[10] Jie Xu,et al. Sirtuin5 contributes to colorectal carcinogenesis by enhancing glutaminolysis in a deglutarylation-dependent manner , 2018, Nature Communications.
[11] Zhe Wang,et al. SHMT2 Desuccinylation by SIRT5 Drives Cancer Cell Proliferation. , 2018, Cancer research.
[12] Liang Chang,et al. SIRT5 promotes cell proliferation and invasion in hepatocellular carcinoma by targeting E2F1. , 2017, Molecular medicine reports.
[13] C. Steegborn,et al. Mechanism-Based Inhibitors of the Human Sirtuin 5 Deacylase: Structure-Activity Relationship, Biostructural, and Kinetic Insight. , 2017, Angewandte Chemie.
[14] Laura G. Dubois,et al. A Class of Reactive Acyl-CoA Species Reveals the Non-enzymatic Origins of Protein Acylation. , 2017, Cell metabolism.
[15] X. Niu,et al. Desuccinylation of pyruvate kinase M2 by SIRT5 contributes to antioxidant response and tumor growth , 2016, Oncotarget.
[16] Yajun Huang,et al. A Selective Cyclic Peptidic Human SIRT5 Inhibitor , 2016, Molecules.
[17] E. Borazan,et al. High-throughput screening of Sirtuin family of genes in breast cancer. , 2016, Gene.
[18] Hening Lin,et al. The Substrate Specificity of Sirtuins. , 2016, Annual review of biochemistry.
[19] Y. Xiong,et al. SIRT5 promotes IDH2 desuccinylation and G6PD deglutarylation to enhance cellular antioxidant defense , 2016, EMBO reports.
[20] Christian M. Metallo,et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth , 2016, Nature.
[21] Johan Auwerx,et al. Metabolomics-assisted proteomics identifies succinylation and SIRT5 as important regulators of cardiac function , 2016, Proceedings of the National Academy of Sciences.
[22] Hening Lin,et al. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. , 2016, Cancer cell.
[23] P. Giannakakou,et al. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. , 2016, Cancer cell.
[24] Steven J. M. Jones,et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.
[25] Matthew J. Rardin,et al. SIRT5 Regulates both Cytosolic and Mitochondrial Protein Malonylation with Glycolysis as a Major Target. , 2015, Molecular cell.
[26] Yingming Zhao,et al. Metabolic Regulation by Lysine Malonylation, Succinylation, and Glutarylation* , 2015, Molecular & Cellular Proteomics.
[27] M. Russo,et al. SIRT5 regulation of ammonia-induced autophagy and mitophagy , 2015, Autophagy.
[28] Min Zhang,et al. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer , 2014, Tumor Biology.
[29] M. Hirschey,et al. Nonenzymatic protein acylation as a carbon stress regulated by sirtuin deacylases. , 2014, Molecular cell.
[30] Yingming Zhao,et al. Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. , 2014, Cell metabolism.
[31] Mong-Hong Lee,et al. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies , 2014, Cancer biology & medicine.
[32] Matthew J. Rardin,et al. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. , 2013, Cell metabolism.
[33] X. Chen,et al. SIRT5 desuccinylates and activates SOD1 to eliminate ROS. , 2013, Biochemical and biophysical research communications.
[34] J. Auwerx,et al. Metabolic Characterization of a Sirt5 deficient mouse model , 2013, Scientific Reports.
[35] Yingming Zhao,et al. SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. , 2013, Molecular cell.
[36] A. Snowman,et al. Inositol Polyphosphate Multikinase Is a Coactivator of p53-Mediated Transcription and Cell Death , 2013, Science Signaling.
[37] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[38] A. Regev,et al. The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism , 2012, Cell.
[39] Tobias Rumpf,et al. Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5. , 2012, ACS medicinal chemistry letters.
[40] Hening Lin,et al. Protein lysine acylation and cysteine succination by intermediates of energy metabolism. , 2012, ACS chemical biology.
[41] Johan Auwerx,et al. Sirtuins as regulators of metabolism and healthspan , 2012, Nature Reviews Molecular Cell Biology.
[42] Hening Lin,et al. Thiosuccinyl peptides as Sirt5-specific inhibitors. , 2012, Journal of the American Chemical Society.
[43] Balaraman Kalyanaraman,et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. , 2012, Free radical biology & medicine.
[44] Johan Auwerx,et al. Sirt5 Is a NAD-Dependent Protein Lysine Demalonylase and Desuccinylase , 2011, Science.
[45] Yi Zhang,et al. The First Identification of Lysine Malonylation Substrates and Its Regulatory Enzyme* , 2011, Molecular & Cellular Proteomics.
[46] P. Pandolfi,et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. , 2011, Cancer cell.
[47] Hanna Y. Irie,et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment , 2009, Nature.
[48] Brian C. Smith,et al. Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide. , 2007, Biochemistry.
[49] Zhiyuan Hu,et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.
[50] H. Iwase,et al. [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[51] Jeffrey W Pollard,et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.
[52] T. Jacks,et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.
[53] R. Cardiff,et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.
[54] L. Guarente,et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase , 2000, Nature.
[55] R. Cardiff,et al. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.